These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 23869896)
1. Brain natriuretic peptide and NT-proBNP levels reflect pulmonary artery systolic pressure in trekkers at high altitude. Woods DR; Mellor A; Begley J; Stacey M; O'Hara J; Hawkins A; Yarker J; Foxen S; Smith C; Boos C Physiol Res; 2013; 62(6):597-603. PubMed ID: 23869896 [TBL] [Abstract][Full Text] [Related]
2. Cardiac biomarkers at high altitude. Mellor A; Boos C; Holdsworth D; Begley J; Hall D; Lumley A; Burnett A; Hawkins A; O'Hara J; Ball S; Woods D High Alt Med Biol; 2014 Dec; 15(4):452-8. PubMed ID: 25330333 [TBL] [Abstract][Full Text] [Related]
3. Choice of marker for assessment of RV dysfunction in acute pulmonary embolism : NT-proBNP, pulmonary artery systolic pressure, mean arterial pressure, or blood pressure index. Ates H; Ates I; Kundi H; Yilmaz FM Herz; 2017 Dec; 42(8):758-765. PubMed ID: 27966013 [TBL] [Abstract][Full Text] [Related]
4. NT-proBNP does not rise on acute ascent to high altitude. Toshner MR; Thompson AA; Irving JB; Baillie JK; Morton JJ; Peacock AJ High Alt Med Biol; 2008; 9(4):307-10. PubMed ID: 19115915 [TBL] [Abstract][Full Text] [Related]
5. Severe acute mountain sickness, brain natriuretic peptide and NT-proBNP in humans. Woods DR; Begley J; Stacey M; Smith C; Boos CJ; Hooper T; Hawkins A; Hodkinson P; Green N; Mellor A Acta Physiol (Oxf); 2012 Jul; 205(3):349-55. PubMed ID: 22222437 [TBL] [Abstract][Full Text] [Related]
6. Lack of association between chronic exposure to biomass fuel smoke and markers of right ventricular pressure overload at high altitude. Caravedo MA; Painschab MS; Davila-Roman VG; De Ferrari A; Gilman RH; Vasquez-Villar AD; Pollard SL; Miranda JJ; Checkley W; Am Heart J; 2014 Nov; 168(5):731-8. PubMed ID: 25440802 [TBL] [Abstract][Full Text] [Related]
7. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241 [TBL] [Abstract][Full Text] [Related]
9. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. Forfia PR; Watkins SP; Rame JE; Stewart KJ; Shapiro EP J Am Coll Cardiol; 2005 May; 45(10):1667-71. PubMed ID: 15893185 [TBL] [Abstract][Full Text] [Related]
10. B-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress. Bal L; Thierry S; Brocas E; Van de Louw A; Pottecher J; Hours S; Moreau MH; Perrin Gachadoat D; Tenaillon A Acta Anaesthesiol Scand; 2006 Mar; 50(3):340-7. PubMed ID: 16480468 [TBL] [Abstract][Full Text] [Related]
12. B-type natriuretic peptides for the evaluation of exercise intolerance. Mueller C; Maeder MT; Christ A; Reichlin T; Staub D; Noveanu M; Breidthardt T; Potocki M; Brutsche MH Am J Med; 2009 Mar; 122(3):265-72. PubMed ID: 19272488 [TBL] [Abstract][Full Text] [Related]
13. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324 [TBL] [Abstract][Full Text] [Related]
14. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301 [TBL] [Abstract][Full Text] [Related]
15. NT-proBNP and BNP values in cardiac patients with different degree of left ventricular systolic dysfunction. Kotaska K; Popelova J; Tiserova M; Telekes P; Vrzanova M; Bronsky J; Halacova M; Kukacka J; Prusa R Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):125-30. PubMed ID: 16936915 [TBL] [Abstract][Full Text] [Related]
16. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461 [TBL] [Abstract][Full Text] [Related]
17. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Luchner A; Hengstenberg C; Löwel H; Riegger GA; Schunkert H; Holmer S Hypertension; 2005 Jul; 46(1):118-23. PubMed ID: 15939804 [TBL] [Abstract][Full Text] [Related]
18. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349 [TBL] [Abstract][Full Text] [Related]
19. [Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.]. Avdeev SN; Gaynitdinova VV; Tsareva NA; Merzhoeva ZM Klin Lab Diagn; 2018; 63(6):333-337. PubMed ID: 30702222 [TBL] [Abstract][Full Text] [Related]
20. Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure. Zuber M; Cuculi F; Attenhofer Jost CH; Kipfer P; Buser P; Seifert B; Erne P Scand Cardiovasc J; 2009; 43(5):324-9. PubMed ID: 19247872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]